Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial

  • The PLOS ONE Staff

There is an error in affiliation 3 for author Darren P. Baker. Affiliation 3 should be: Sanofi Genzyme, Cambridge, Massachusetts, United States of America.

There is an error in the caption for Fig 2. Please see the complete, correct Fig 2 caption here. The publisher apologizes for these errors.

thumbnail
Download:
Fig 2. IFN β-1a treatment effect on survival of patients with EVD.

Survival curves for patients with EVD receiving supportive care only (n = 21) (solid line) or supportive care plus IFN β-1a treatment (n = 9) (dashed line). Survival was calculated from the date of consent for those receiving IFN β-1a treatment and date of admission for those in the control cohort, to the date of death. Survival plots were based on Kaplan-Meier estimates and the plots were compared using the log rank test (p = 0.026).

https://doi.org/10.1371/journal.pone.0175930.g001

Reference

  1. 1. Konde MK, Baker DP, Traore FA, Sow MS, Camara A, Barry AA, et al. (2017) Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS ONE 12(2): e0169255. pmid:28225767

Citation: The PLOS ONE Staff (2017) Correction: Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS ONE 12(4): e0175930. https://doi.org/10.1371/journal.pone.0175930

Published: April 12, 2017

Copyright: © 2017 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.